Targeted Nano-Bioadhesives and Precision Microbiome Engineering: A Paradigm Shift for Eradicating Refractory Helicobacter pylori Infection with Unprecedented Safety and Efficacy

Helicobacter pylori infection represents a significant global health burden, contributing to pathologies ranging from peptic ulcers to gastric adenocarcinoma. The escalating prevalence of antimicrobial resistance (AMR) severely compromises the efficacy of current eradication therapies, creating an urgent need for novel therapeutic paradigms. This paper introduces a revolutionary, dual-pillar theoretical framework integrating: (1) Precision-engineered, targeted nano-bioadhesives (TNBs), designed for localized, high-concentration delivery of a multi-modal payload—including novel antimicrobials and biofilm disruptors—directly at the site of infection; and (2) Precision Microbiome Engineering (PME), which utilizes engineered probiotics and prebiotics to restore gastric homeostasis and prevent recurrence. This synergistic approach is designed to overcome AMR by achieving high local drug concentrations, dismantle protective bacterial biofilms, and minimize systemic toxicity, thereby offering an unprecedented safety and efficacy profile. The framework represents a paradigm shift from conventional antibiotic regimens towards a sustainable and curative strategy, holding the potential to transform refractory H. pylori infection into a readily manageable condition and significantly reduce the global incidence of its severe long-term sequelae.